Based on our results, we propose the possible use of miR-425-5p as a stool and/or blood-based biomarker, which could represent reliable and non-invasive methods of categorizing poor prognostic KRAS-mutated CRC patients. This evidence concerns the gene KRAS and colorectal carcinoma.